Newton Biocapital S.A. (NBC)

https://www.newtonbiocapital.com

LinkedIn: https://www.linkedin.com/company/newton-biocapital-fund

Newton Biocapital (NBC) is a VC firm focused on early-stage life sciences companies targeting chronic health conditions. NBC is among the eight VC firms certified by AMED in Japan to boost the pharma ecosystem and the only one with offices in Japan /Europe. NBC’s diversified team of experts and its presence in Japan/Europe enable NBC to identify and select the most promising companies based on the outstanding research ecosystem in these two regions. NBC provides investment opportunities that can help patients and society, as well as foster growth of the Japanese/European biotech ecosystems. NBC is a hands-on investor and leverages its expertise to help its portfolio companies focus on the right indication and clinical trial design, thereby helping them progress successfully through the challenging early drug development phases up to the proof of concept in patients. NBC enables time- and cost-effective translation from science to proof of concept in patients that attracts potential acquirers and unlocks value – for patients, companies and investors. *

	Start	2017-01-01 established
	Group	Newton Biocapital (NBC) (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Parthoens, Alain (Newton Biocapital 201810 Managing Director before Vesalius Biocapital)
	Person 2	De Backer, Philippe (Newton Biocapital 202209– Senior Partner formerly Belgian Minister + Secretary of State)

	Region	Brussels
	Country	Belgium
	Street	273 Tervurenlaan
	City	1150 Brussels
	Tel	+32-2-899-7850
		Address record changed: 2022-02-17

Basic data	Employees	n. a.

		* Document for »About Section«: DeuterOncology N.V.. (1/19/23). "Press Release: DeuterOncology Closes €5.65M Series A Financing Round". Liège.

		Record changed: 2024-02-12